Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Published 2018 View Full Article

Authors

Keywords

Journal

DIABETES CARE

Volume 41, Issue 10, Pages 2136-2146

Publisher

American Diabetes Association

Online

2018-08-07

DOI

10.2337/dc18-0680

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

DIABETES CARE

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Publish scientific posters with Peeref

Ask a Question. Answer a Question.